Lyell Immunopharma, Inc. (LYEL)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $7.51
- As of
Kresmion compiles this page from LYEL's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Lyell Immunopharma, Inc. (LYEL): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-10.
See the full LYEL dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for LYEL on one page. Preview it with sample data, then open it live with a free account.
Preview the LYEL dossierActive signals for LYEL
- highINSTITUTIONAL_SURGE
TWO SIGMA INVESTMENTS, LP added +357% to LYEL (2026Q2)
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 6.7%, EPS $-1.92 vs $-2.0579 estimate
- highCONSENSUS_BUY
3 tracked funds increased LYEL this 2026Q1 - institutional consensus
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +85% to LYEL (2026Q1)
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +682% to LYEL (2026Q1)
FREE, NO ACCOUNT
Every signal on LYEL, as it fires
You are seeing 5 of 12 signals recorded on LYEL since 2026-05-29.
The five above landed across 3 days. The other 7 were recorded on 2 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in LYEL (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 55083R203 · 2026Q2 | $5.2M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 55083R203 · 2026Q2 | $1.8M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 55083R203 · 2026Q2 | $744K | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 55083R203 · 2026Q2 | $366K | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 55083R203 · 2026Q2 | $263K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, LYEL
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
LYEL against its peers
LYEL's operating margin of -748344.4% ranks in the 2nd percentile of 20 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | LYEL | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 36000 USD | 26.4M USD | 3 | 18 |
| Gross margin | n/a | 58.3% | n/a | 5 |
| Operating margin | -748344.4% | -351.3% | 2 | 20 |
| Net margin | -762355.6% | -202.2% | 2 | 21 |
| Return on equity | -110.6% | -49.6% | 30 | 21 |
| 1 year | -55.4% | -16.4% | 14 | 17 |
Peers (24): CGEN, CUE, TRDA, ELDN, RNAC, IVVD, NGEN, XGN, ACOG, IPHA, ORMP, WHWK, NAGE, ALEC, PRQR, DTIL, PLX, MGNX, PYXS, CAMP, CHRS, MENS, IFRX, NBP. Left out: VRXA (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (LYEL: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow LYEL on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to LYEL for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.